A range of physiological functions are associated with Ang IV, including the facilitation of memory (Braszko et al., 1988; Wright et al., 1993 Wright et al., , 1999 , modulation of sodium uptake in the kidney (Hamilton et al., 2001) , and vasodilatory effects (Haberl et al., 1991; Kramar et al., 1997 Kramar et al., , 1998 . These actions are mediated by a specific binding site that has been termed the AT 4 receptor. We previously isolated an alternative AT 4 ligand, LVV-hemorphin-7 (LVVYPWTQRF), from the sheep cerebral cortex using a multistep procedure of reverse-phase and ion-exchange chromatography based on its ability to compete with 125 I-Ang IV for the AT 4 receptor (Moeller et al., 1997) . LVV-hemorphin-7 shares identical sequence to residues 30 to 39 of sheep ␤-globin and residues 32 to 41 of the ␤-, ␦-, ␥-, and ⑀-human globin. Various studies have demonstrated that LVV-hemorphin-7 mimics many biological actions of Ang IV. At the cellular level, LVV-hemorphin-7 stimulates DNA synthesis in SK-N-MC cells , whereas in hippocampal slices, the decapeptide enhances the potassium-evoked release of acetylcholine . We have recently demonstrated that central administration of LVV-hemorphin-7 enhances spatial learning (J. Lee, A. L. Albiston, A. M. Allen, F. A. Mendelsohn, S. E. Ping, G. L. Barrett, M. Murphy, M. J. Morris, S. G. McDowall, and S. Y. Chai, manuscript submitted for publication).
We have identified the AT 4 receptor as the transmembrane enzyme insulin-regulated aminopeptidase (IRAP) via mass spectral analysis of tryptic peptides generated from AT 4 receptor purified from bovine adrenal membranes . Analysis of the biochemical and pharmacological properties of IRAP confirm that it is the AT 4 receptor. We have also demonstrated that both Ang IV and LVV-hemorphin-7 inhibit the catalytic activity of IRAP, suggesting enzyme inhibition as one mechanism by which AT 4 ligands exert their effects ). For coherence, we describe the previously named AT 4 receptor agonists such as Ang IV and LVV-hemorphin-7 as AT 4 ligands and the AT 4 receptor as IRAP.
IRAP belongs to the M1 family of zinc metallopeptidases that is characterized by the zinc binding motif HEXXH(X) 18 -E and the exopeptidase motif GXMEN. IRAP is a type II membranespanning protein such that when at the plasma membrane the catalytic site is extracellular (Keller et al., 1995) . The enzyme was initially defined as specifically cleaving the N-terminal amino acid CysXaa-, in which the half-cystine residue is involved in a disulfide loop, notably in oxytocin or vasopressin, but in vitro has also been demonstrated to cleave a range of peptides not containing disulfide loops (Matsumoto and Mori, 1998; Matsumoto et al., 2000) . Our preliminary studies indicate that AT 4 ligands are not cleaved by IRAP (R. A. Lew, T. Mustafa, S. Ye, S. G. McDowall, S. Y. Chai, and A. L. Albiston, manuscript submitted for publication).
Considering the wide-ranging effects mediated by AT 4 ligands, an understanding of the structural requirements for the ligand-enzyme interaction will be beneficial for the design of metabolically stable inhibitors of IRAP. The critical amino acids required for Ang IV binding to IRAP have been identified (Sardinia et al., 1993 (Sardinia et al., , 1994 Krishnan et al., 1999) . The presence of an amino-terminal valine, and more precisely, a primary ␣-amine in the L-amino acid conformation in position 1, seems to be important in the binding process. Glycine substitutions at positions 1, 2, or 3 of Ang IV greatly reduce affinity for IRAP, whereas substitutions at positions 4, 5, or 6 of Ang IV have little effect (Sardinia et al., 1993) . Moreover, N-terminal elongation of Ang IV results in a marked reduction in affinity, whereas C-terminally extended peptides bind to the receptor with an affinity similar to that of the native ligand (Sardinia et al., 1993) . Thus, the Nterminal residues of the Ang IV peptide are critical for receptor binding, whereas the C-terminal portion plays a less critical role.
Interestingly, despite a similar binding affinity for IRAP, LVV-hemorphin-7 (LVVYPWTQRF) shares little sequence homology to Ang IV (VYIHPF). Considering that this biologically active peptide is more stable than Ang IV (Moeller et al., 1999) , LVV-hemorphin-7 may be a useful template for the design of peptidomimetics targeting the IRAP protein. In the current study, we set out to determine the structural requirements of LVV-hemorphin-7 binding to IRAP. To achieve this aim, a series of N-and C-terminally modified and alaninesubstituted analogs of LVV-hemorphin-7 were screened for their abilities to compete for 125 I-Ang IV binding in sheep adrenal and cerebellar membranes. Moreover, selected truncated LVV-hemorphin-7 analogs were also analyzed for their ability to bind to and inhibit the recombinant form of human IRAP.
Materials and Methods

Synthesis and Preparation of Peptides
Truncated analogs of LVV-hemorphin-7 and Val-Tyr-Pro-motif extended peptides were synthesized by Mimotopes (Clayton, Victoria, Australia). The N-terminally extended analogs and Ala-substituted analogs of LVV-hemorphin-7 were synthesized in the peptide laboratory at the Howard Florey Institute (University of Melbourne, Parkville, Victoria, Australia), using the continuous flow Fmocmethodology (Wade et al., 2001) . Peptides were dissolved in 0.05 M acetic acid and stored as 1 mM stock solutions at Ϫ20°C. The fluorescent substrate Leu-␤-naphthylamide (Leu-␤-NA), its cleavage product ␤-naphthylamine, and other reagents were purchased from Sigma Chemical (Castle Hill, NSW, Australia).
Tissue Samples
Sheep adrenal glands and cerebellum obtained from the abattoir were frozen in isopentane on dry ice at Ϫ40°C and stored at Ϫ80°C.
Expression of Human IRAP in Human Embryonic Kidney (HEK) 293T Cells
HEK293T cells were transiently transfected with either pCI-IRAP (a gift from M. Tsujimoto, Department of Obstetrics and Gynaecology, Nagoya University School of Medicine, Japan) or empty vector using LipofectAMINE transfection reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions.
Membrane Preparation. Membranes were prepared as described previously . In brief, tissues and transfected cells were suspended in 50 mM Tris-HCl pH 7.4, homogenized for 10 s, and centrifuged at 600g for 5 min at 4°C to remove cellular debris. The supernatant was incubated for 20 min at 65°C followed by centrifugation at 50,000g for 20 min at 20°C. Membranes were resuspended in 50 mM Tris, 5 mM EDTA, 150 mM sodium chloride buffer containing 100 M phenylmethylsulfonyl fluoride, 20 M bestatin, 100 M phenanthrolene, and 0.1% bovine serum albumin.
Western Blot Analysis of IRAP in Ovine Adrenal and Cerebellum Membranes
Ovine adrenal and cerebellum crude membranes (200 g of total protein) were run on SDS-polyacrylamide gel electrophoresis. The resolved proteins were transferred to a Protran BA nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) and immunodetected using an in-house rabbit anti-IRAP polyclonal antibody (raised against amino acids 25-47 of human IRAP). The primary antibody was detected using horseradish peroxidase-conjugated sheep anti-rabbit secondary antibody (Chemicon International, Temecula, CA); enhanced chemiluminescence was used to detect conjugated horseradish peroxidase activity and was captured using a luminescent image analyzer LAS-1000 plus (FujiFilm, Kanagawa, Japan).
Binding Assays
Competition. Crude membranes (20 g for transfected cells and 65 g for ovine tissues) of protein were incubated with 0.5 Ci/ml of 125 I-Ang IV and increasing concentrations (10 Ϫ12 -10 Ϫ5 M) of unlabeled peptide, for 2 h at 37°C. Bound and free radioligand was separated using the standard filtration method as described previously (Moeller et al., 1997) . The radioligand binding data were analyzed using the GraphPad Prism program (GraphPad Software Inc., San Diego, CA) to determine the IC 50 value for each analog. LVVhemorphin-7 or Ang IV was included for each set of experiments serving as controls.
Saturation. Binding studies were carried out by incubating transfected cell membranes (2 g) in the presence of increasing concentrations (1-12,000 pM) of 125 I-Ang IV, and nonspecific binding was determined in the presence of 10 M of unlabeled Ang IV; K d and B max values obtained by Scatchard analysis. K i values were obtained using the equation
Enzyme Inhibition Assay
For enzyme activity assays, cell membranes were prepared as described above, omitting EDTA in the harvesting buffer. The membrane pellet was resuspended in 20 mM HEPES, 255 mM sucrose, 100 mM NaCl, pH 7.4, with protease inhibitors (10 g/ml aprotinin, 10 M leupeptin, 1 M pepstatin, and 1 mM phenylmethylsulfonyl fluoride), snap frozen on dry ice, and stored at Ϫ70°C for up to 3 months.
Aliquots of crude membranes were thawed, centrifuged at 9000g in a tabletop Microfuge at 4°C for 15 min, and the supernatant discarded. Membranes were resuspended in Tris-buffered saline (25 mM Tris-HCl, 125 mM NaCl, pH 7.4) containing 1% Triton X-100 at a protein concentration of 1 mg/ml, and rotated gently for at least 5 h at 4°C to solubilize membrane proteins. After solubilization, the membranes were pelleted by centrifugation as described above, the supernatant stored at 4°C, and used in assays within 24 h. IRAP activity was monitored by the increase in fluorescence after cleavage of Leu-␤-NA. Assays were performed in black 96-well microtiter plates: each well contained 2 g of human IRAP-HEK293T-solubilized membrane protein, 25 M Leu-␤-NA, and the peptide of interest in a final volume of 200 l of Tris-buffered saline. Reactions proceeded at 37°C for 30 min in a thermostated fMax fluorescence microplate reader (Molecular Devices Corp., Sunnyvale, CA), before reading the fluorescence (excitation ϭ 320 nm, emission ϭ 420 nm). The ability of each peptide to inhibit IRAP was determined over a range of peptide concentrations (0.01-10 M), with each concentration being assayed in triplicate in two separate experiments. 
Statistics
The IC 50 value for each peptide was determined and expressed as the mean Ϯ S.E.M. (GraphPad Prism; GraphPad Software Inc.). Statistical differences between IC 50 values for the various peptides were determined by one-way analysis of variance (GraphPad Prism).
Where there was a significant effect between LVV-hemorphin-7 and the modified peptide (P Ͻ 0.05) on analysis of variance, Bonferroni's post hoc test was used to determine the significance of difference between the two peptides. 
Results
Affinity for Central and Peripheral IRAP Site. Western blot analysis clearly demonstrates a size difference between the sheep cerebellum and adrenal gland IRAPs as has previously been described for both the rat and bovine central and peripheral tissues (Keller et al., 1995; Zhang et al., 1999) . The molecular mass of ovine adrenal IRAP is 165 kDa and ovine cerebellum IRAP is 145 kDa (Fig. 1) . However, there were no statistically significant differences in the IC 50 values obtained, between the cerebellum and adrenal IRAP, for any of the peptides tested (Tables 1-4) . (Table  1) .
C-Terminal Deletions of LVV-Hemorphin-7. Deletions of the C-terminal residues
Val-Tyr-Pro-Motif Extended Peptides. Previous structure-activity studies with Ang IV revealed that the minimum requirement of binding to IRAP is the tripeptide VYI, which binds to IRAP with weak affinity (IC 50 ϭ 0.48 M) (Sardinia et al., 1993) . We therefore investigated the effect of sequential C-terminal or N-terminal extension of the tripeptide Val-Tyr-Pro, using amino acid sequences from LVV-hemorphin-7. In both the sheep adrenal and cerebellar membranes, Val-Tyr-Pro failed to compete for 125 I-Ang IV binding even at concentrations of Ͼ10 M. The addition of Trp to the C terminus of the peptide (Val-Tyr-Pro-Trp) increased the affinity in both adrenal and cerebellar membranes (IC 50 ϭ 17.2 and 19.0 nM, respectively) ( Table 2 ). Subsequent addition of a Thr residue (Val-Tyr-Pro-Trp-Thr) increased the affinity by a further 10-fold (IC 50 ϭ 1.9 and 1.1 nM, respectively), with no further increase with addition of the last three residues, Gln, Arg, and Phe. Addition of both Leu and Val to the N terminus of Val-Tyr-Pro (Leu-Val-Val-Tyr-Pro) increased the I͔-Ang IV binding to crude membranes in the presence of LVV-H7 analogs was performed as described under Materials and Methods. IRAP enzymatic activity was determined by the hydrolysis of the synthetic substrate, Leu-␤-NA in the presence or absence of LVV-H7 analogs (n ϭ 3 for each peptide).
Peptide
Enzyme tide's affinity for IRAP. In line with this, substitutions, deletions, or extensions of the C-terminal residues of Ang IV had little to modest effects on IRAP binding (Sardinia et al., 1993) . These results support the notion that the N-terminal residues primarily determine the affinity of a ligand for IRAP.
To determine the influence of amino acid side chains on the ligand-enzyme interaction, a selected group of residues (Tyr 4 Pro 5 Trp 6 Thr 7 ) from LVV-hemorphin-7 were substituted with alanine. Substitution of either Tyr 4 or Trp 6 with alanine results in a significant decrease in affinity, suggesting that these aromatic amino acids play a role in determining affinity for IRAP. The Tyr 2 residue in Ang IV is important for IRAP binding, due to its hydrophobic nature and planar geometry (Krishnan et al., 1999) . Sardinia et al. (1993) demonstrated that the tripeptide VYI is the minimum requirement for Ang IV binding to IRAP. Ang IV and LVV-hemorphin-7 sequence both share the sequence VY in the N terminus. This led us to investigate the binding of the tripeptide VYP, derived from the LVVYP-WTQRF sequence, to IRAP. The VYP peptide displayed poor affinity for IRAP in both cerebellar and adrenal membranes. However, the addition of the hydrophobic amino acid Trp to the C terminus of VYP (VYPW) improves the affinity significantly. Taken together, the presence of a hydrophobic amino acid at the C-terminal end of VYP may be important for high-affinity binding. In support of this, a hydrophobic amino acid is required at position three of Ang IV to achieve highaffinity binding (Krishnan et al., 1999) . Alternatively, the addition of the Leu 1 Val 2 residues to the N terminus of VYP peptide also improves binding significantly. Thus, in the absence of the C-terminal residues, the Leu 1 Val 2 amino acids may be important for binding to IRAP, possibly by altering the tertiary conformation of the VYP peptide to maximize peptide-enzyme interaction.
A limitation of competition binding studies to delineate the structural requirements for high-affinity binding to IRAP (AT 4 receptor) is that they are performed in the presence of chelating agents (phenanthroline and/or EDTA), whereas in vivo IRAP, a zinc metalloproteinase, is present with a bound zinc. Therefore, the enzyme inhibition assay is a useful system to assess the structural requirements for high-affinity binding of AT 4 ligands to IRAP in a biologically relevant context. AT 4 ligands, including LVV-hemorphin-7, are not substrates of IRAP, because we have recently demonstrated that HEK293T cells transfected with IRAP do not degrade these peptides beyond the level observed for mock-transfected cells (Ͻ15% over 4 h) (R. A. Lew, T. Mustafa, S. Y. Chai, and A. L. Albiston, unpublished data). LVV-hemorphin-7 and the five selected truncated analogs inhibited the aminopeptidase activity of IRAP in the same rank order as obtained for competition binding. However, the K i values obtained for the truncated LVV-hemorphin-7 analogs using the enzyme inhibition and the competition binding assays differ markedly. The K i values obtained from the enzyme inhibition assay were up to 100-fold lower compared with values obtained from the competition binding assay. Val-TyrPro-Trp-Thr-Gln-Arg-Phe the most potent peptide in both the enzyme inhibition and the competition binding assays had K i values of 56 and 1 nM determined from the respective assays. The differences in the K i values obtained from the two assays is likely to be due to the presence or absence of zinc bound to IRAP altering the affinity of the LVV-hemorphin-7 analogs.
Beyond the prerequisite for a free N terminus, the requirements for substrate binding to IRAP are difficult to define. The enzyme has previously been defined as specifically cleaving the N-terminal amino acid CysXaa-, in which the halfcystine residue is involved in a disulfide loop, notably in oxytocin, vasopressin, and somatostatin (Herbst et al., 1997) . N-Terminal cysteine residues seem to be the preferential targets for the enzyme; however, other peptides that possess N-terminal cysteine residues and intramolecular disulfide bonds, such as calcitonin and endothelin, are not cleaved by the enzyme. Other peptides that are readily cleaved by IRAP include Lys-bradykinin, met-enkephalin, dynorphin A, neurokinin A, and neuromedin B (Herbst et al., 1997) , which possess a range of N-terminal residues. In contrast to AT 4 ligands the affinities of such substrates are in the mid-micromolar range, as is common with peptidases.
In conclusion, we have demonstrated that the Val 3 residue is crucial for LVV-hemorphin-7 binding to IRAP. This observation is in keeping with the suggestion that a hydrophobic amino acid is required at the N terminus for high-affinity binding to IRAP. In contrast, the C-terminal domain of LVVhemorphin-7 does not seem to play an important role in determining ligands affinity for IRAP. The results from the current study indicate that the minimal sequence required for high-affinity binding and inhibition of IRAP is VYPWT. Modification of this truncated analog of LVV-hemorphin-7, using systematic cyclization and bicyclization, may yield specific, potent inhibitor(s) of IRAP.
